{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00026813", "CSN": null, "TRF": "ORD_1563049_01", "MRN": "49243643", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1274421", "clinicalId": "1275777", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1563049_01", "SampleName": "US1493770.01", "Version": "0", "Sample": {"FM_Id": "ORD_1563049_01", "SampleId": "US1493770.01", "BlockId": "S112-02961F", "TRFNumber": "ORD_1563049_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_02_08", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "50", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10039", "MRN": "49243643", "FullName": "\u694a\u601d\u79c0", "FirstName": "Ssu Hsiu", "LastName": "Yang", "SubmittedDiagnosis": "Kidney carcinoma (NOS)", "Gender": "Female", "DOB": "1955_09_22", "OrderingMD": "\u5f35\u5ef6\u9a4a", "OrderingMDId": "109266", "Pathologist": "\u5f6d\u6631\u749f", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Kidney", "CollDate": "2023_01_30", "ReceivedDate": "2023-02-20 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Urothelial Carcinoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "23", "clinicalTrialCount": "23", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "BCL6", "isVUS": "true", "variantName": "D17N"}, {"geneName": "BRCA2", "isVUS": "true", "variantName": "H523R"}, {"geneName": "EP300", "isVUS": "true", "variantName": "P1875S"}, {"geneName": "FLT3", "isVUS": "true", "variantName": "V491fs*11"}, {"geneName": "KDR", "isVUS": "true", "variantName": "E732K"}, {"geneName": "LTK", "isVUS": "true", "variantName": "R606Q"}, {"geneName": "MSH2", "isVUS": "true", "variantName": "E809K"}, {"geneName": "MST1R", "isVUS": "true", "variantName": "V366F"}, {"geneName": "NOTCH2", "isVUS": "true", "variantName": "L823R"}, {"geneName": "PARP1", "isVUS": "true", "variantName": "V979M"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "FGFR1", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "FGFR1 encodes the protein fibroblast growth factor receptor 1, which plays key roles in regulation of the cell cycle and angiogenesis and is an upstream regulator of the RAS, MAPK, and AKT signaling pathways (Turner and Grose, 2010; 20094046). Amplification of FGFR1 has been correlated with protein expression (Kohler et al., 2012; 22648708, Kim et al., 2013; 23182986) and may predict pathway activation and sensitivity to therapies targeting this pathway (Andr\u00e9 et al., 2014; 24508104, Dienstmann et al., 2014; 24265351). In the TCGA datasets, FGFR1 amplification and mutation have each been reported in 0_1% of renal cell carcinomas across clear cell, papillary, and chromophobe subtypes (cBioPortal, Feb 2022) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Intense expression of FGFR1 protein was associated with shorter PFS by univariate and multivariate analysis among patients with metastatic renal cell carcinoma treated with sorafenib in 1 study (Ho et al., 2015; 25900027). Alterations that activate FGFR1 may predict sensitivity to selective FGFR inhibitors including erdafitinib (Loriot et al., 2019; 31340094, Tabernero et al., 2015; 26324363, Karkera et al., 2017; 28416604, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Necchi et al., 2018; ESMO Abstract 900P, Subbiah et al., 2022; 35176457), infigratinib (Pal et al., 2018; 29848605, Pal et al., 2020; 32208524), futibatinib (Bahleda et al., 2020; 32622884, Meric_Bernstam et al., 2022; 34551969, Kasbekar et al., 2020; 32649766), rogaratinib (Schuler et al., 2019; 31405822), Debio 1347 (Sait et al., 2021; 34250399, Voss et al., 2019; 30745300), and derazantinib (Papadopoulos et al., 2017; 28972963) or to multikinase inhibitors such as pazopanib (Cheng et al., 2017; 29223982, Yuan et al., 2016; SABCS Abstract P6_16_08) and ponatinib (Khodaoust et al., 2015; 26055304, Tanasi et al., 2019; 31434701, Strati et al., 2018; 29119847, Kreil et al., 2015; ASH Abstract 2812). The activity and efficacy of selective FGFR inhibitors for FGFR1_amplified tumors has been modest, with limited responses reported in FGFR1_amplified lung squamous cell carcinoma (SCC) treated with infigratinib (Nogova et al., 2017; 27870574) or AZD457 (Aggarwal et al., 2019; 31195180), in FGFR1_amplifed uterine cancer treated with pemigatinib (Subbiah et al., 2022; 35176457), and no responses reported among patients with FGFR1_amplified breast cancer treated with infigratinib (Nogova et al., 2017; 27870574) or pemigatinib (Subbiah et al., 2022; 35176457). Two case studies reported PRs in patients with FGFR1_amplified breast cancer treated with pazopanib (Cheng et al., 2017; 29223982, Yuan et al., 2016; SABCS Abstract P6_16_08).", "Include": "true", "ClinicalTrialNote": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04736706", "Include": "true"}, {"nctId": "NCT05024214", "Include": "true"}, {"nctId": "NCT05014828", "Include": "true"}, {"nctId": "NCT04169672", "Include": "true"}, {"nctId": "NCT05098847", "Include": "true"}, {"nctId": "NCT03564691", "Include": "true"}, {"nctId": "NCT04586231", "Include": "true"}, {"nctId": "NCT04977453", "Include": "true"}, {"nctId": "NCT04626479", "Include": "true"}, {"nctId": "NCT04626518", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MTAP", "Include": "true", "Alterations": {"Alteration": {"Name": "loss exons 2_8", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss exons 2_8"}}, "Interpretation": "MTAP encodes S_methyl_5 _thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity (Limm et al., 2016; 27479139, Tang et al., 2014; 25387827). Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment (Kirovski et al., 2011; 21356366, Limm et al., 2013; 23265702, Stevens et al., 2009; 19097084), thereby reducing intracellular arginine methylation (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360) and altering cell signaling (Limm et al., 2014; 25087184, Stevens et al., 2009; 19097084). MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co_deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized. MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers (Wei et al., 2016; 27929028, Zhao and Zhao, 2016; 27556634); such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma (Kirovski et al., 2011; 21356366), gastrointestinal stromal tumors (Huang et al., 2009; 19887491), mantle cell lymphoma (MCL)(Marce et al., 2006; 16778103), melanoma (Meyer et al., 2010; 20500769, Wild et al., 2006; 16618867), gastric cancer (Kim et al., 2011; 21412930), myxofibrosarcoma (Li et al., 2014; 25426549), nasopharyngeal carcinoma (He et al., 2015; 26656376), ovarian carcinoma (Wei et al., 2016; 27929028) and non_small cell lung cancer (Su et al., 2014; 24969958). MTAP loss was not prognostic in pediatric B_cell acute lymphocytic leukemia (Mirebeau et al., 2006; 16818274) or in astrocytoma (Becker et al., 2015; 26088413). However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples (Snezhkina et al., 2016; 27433286), and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM (Bistulfi et al., 2016; 26910893). Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma (Antonopoulou et al., 2015; 25407435, Mccioni et al., 2013; 23816148), esophageal cancer (Hyland et al., 2016; 26635288, Lin et al., 2017; 27960044), osteosarcoma (Zhi et al., 2016; 27994653), and CRC (Gu et al., 2013; 23361049). MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A (Kalev et al., 2021; 33450196, Heist et al., 2019; AACR_NCI_EORTC Abstract B116, Marjon et al., 2016; 27068473) or PRMT5 inhibition (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360). A Phase 1 trial of MAT2A inhibitor AG_270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss (Heist et al., 2019; AACR_NCI_EORTC Abstract B116). Preclinical data suggest that MTAP loss sensitizes cells to S_adenosyl_L_methionine (SAM)_competitive PRMT5 inhibitors (Guccione and Richard, 2019; 31350521), dual PRMT1 and PRMT5 inhibitors (Fedoriw et al., 2019; 31257072, Srour et al., 2019; 31287990, Gao et al., 2019; 30916320), and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S_methyl_5 _thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193 (Smith et al., 2022; 35041419, Briggs et al., 2022; AACR Abstract 3941). In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA (Hansen et al., 2019; 31040154, Tang et al., 2018; 29844120, Munshi et al., 2014; 24928612, de Oliveira et al., 2016; 26751376, Lubin and Lubin, 2009; 19478948, Tang et al., 2012; 22825330, Collins et al., 2012; 22252602, Bertino et al., 2011; 21301207, Coulthard et al., 2011; 21282358, Miyazaki et al., 2007; 17912432, Efferth et al., 2002; 11987241). A Phase 2 study of L_alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP_deficient cancers reported no responses and SD for 24% (13/55) of patients (Kindler et al., 2009; 18618081). Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed (Alhalabi et al., 2022; 35379845).", "Include": "true", "ClinicalTrialNote": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT05094336", "Include": "true"}, {"nctId": "NCT05275478", "Include": "true"}, {"nctId": "NCT05245500", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "RAD51D", "Include": "true", "Alterations": {"Alteration": {"Name": "K91fs*13", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "47.97", "isEquivocal": "false", "name": "K91fs*13"}}, "Interpretation": "RAD51D, also known as RAD51L3, is involved in homologous recombination_mediated DNA repair and telomere maintenance (Tarsounas et al., 2004; 15109494, Suwaki et al., 2011; 21821141, Sasaki et al., 2004; 15162012, Smiraldo et al., 2005; 15781618). Germline mutations in RAD51D have been associated with hereditary breast and ovarian cancer (Baker et al. 2015; 25445424, Graffeo et al., 2016; 27734215, Osher et al., 2012; 22415235, Peltarri et al., 2012; 22652533, Gutierrez et al., 2014; 24130102, Loveday et al., 2011; 21822267), and RAD51D mutation carriers have an increased lifetime risk of ovarian cancer, estimated to be 10_12% (Loveday et al., 2011; 21822267, Song et al., 2015; 26261251). Alterations such as seen here may disrupt RAD51D function or expression (Rivera et al., 2017; 28646019, Miller et al., 2004; 14704354, Gruver et al., 2005; 16236763, Hinz et al., 2006; 16522646, Wiese et al., 2006; 16717288, Gruver et al., 2009; 19327148, Fernandes et al., 2019; 30765603). RAD51D mutation has been reported in <0.5% of analyzed kidney tumors (COSMIC, cBioPortal, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210) (Tate et al., 2019; 30371878). Published data investigating the prognostic implications of RAD51D alterations in kidney cancer are limited (PubMed, Mar 2021). Limited preclinical data (Rivera et al., 2017; 28646019, Loveday et al., 2011; 21822267) and clinical evidence in ovarian cancer (Swisher et al., 2017; 27908594, Kondrashova et al., 2017; 28588062, Chandran et al., 2018; DOI: 10.1200/PO.18.00253, O Malley et al., 2017; AACR_NCI_EORTC Abstract LB_A12) indicate that loss or inactivation of RAD51D may confer sensitivity to PARP inhibitors. Loss of functional RAD51D may also predict sensitivity to DNA_damaging drugs such as mitomycin C and cisplatin (Hinz et al., 2006; 16522646, Wiese et al., 2006; 16717288, Rivera et al., 2017; 28646019, Wickramanayake et al., 2012; 22986143). One or more of the RAD51D variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hereditary breast and ovarian cancer syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Inactivating germline mutations in RAD51D are associated with hereditary breast and ovarian cancer (HBOC) syndrome, an autosomal dominant disorder that predisposes patients to breast and ovarian malignancies (Janatova et al., 2015; 26057125, Stafford et al., 2017; 28591191). The risk of ovarian cancer in RAD51D mutation carriers has been estimated to be 10 to 12% (Loveday et al., 2011; 21822267, Song et al., 2015; 26261251). Germline RAD51D mutation has been reported at frequencies of up to 1% in breast and ovarian familial cancer populations without BRCA1/2 mutation (Guti\u00e9rrez_Enr\u00edquez et al., 2014; 24130102, Konstanta, et al., 2018; 30111881, Chen et al., 2018; 30165555). In the appropriate clinical context, germline testing of RAD51D is recommended.", "Include": "true", "ClinicalTrialNote": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04644068", "Include": "true"}, {"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT04991480", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). In the Kidney Renal Clear Cell Carcinoma (ccRCC) and Kidney Renal Papillary Cell Carcinoma TCGA datasets, putative homozygous deletion of both the CDKN2A and CDKN2B genes has been reported in 4.5% and 3% of cases, respectively (cBioPortal, Jul 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). CDKN2A/B deletion has been reported to be one of the most significant copy number alterations in ccRCC (Girgis et al., 2012; 22926558). In a study of sarcomatoid renal cell carcinoma (RCC), CDKN2A alterations were reported in 27% (7/26) of cases, with CDKN2B also altered in 15% (4/26) of these samples (Malouf et al., 2016; 26895810). One study has reported loss of heterozygosity (LOH) on 9p21, which includes the region that encodes CDKN2A and CDKN2B, in 25% of papillary renal cell carcinoma tumors (Maestro et al., 2000; 11037653). Loss due to deletion or hypermethylation of chromosome 9p, which includes the CDKN2A and CDKN2B loci, has been reported at frequencies ranging from 13% to 80% of renal cell carcinoma samples, including ccRCC and papillary subtypes, and has been associated with poor prognosis (Toma et al., 2008; 18592004, Klatte et al., 2009; 19124809, Gunawan et al., 2003; 14559804, Onay et al., 2009; 19641369, Sanz_Casla et al., 2003; 12883879). In addition, loss of chromosome 9p has been associated with advanced tumor grade, disease progression, and overall poor prognosis in both ccRCC and papillary renal cell carcinoma (Klatte et al., 2009; 19124809, Grady et al., 2001; 11490304, Gunawan et al., 2003; 14559804). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). In the Kidney Renal Clear Cell Carcinoma (ccRCC) and Kidney Renal Papillary Cell Carcinoma TCGA datasets, putative homozygous deletion of both the CDKN2A and CDKN2B genes has been reported in 4.5% and 3% of cases, respectively (cBioPortal, Jul 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). CDKN2A/B deletion has been reported to be one of the most significant copy number alterations in ccRCC (Girgis et al., 2012; 22926558). In a study of sarcomatoid renal cell carcinoma (RCC), CDKN2A alterations were reported in 27% (7/26) of cases, with CDKN2B also altered in 15% (4/26) of these samples (Malouf et al., 2016; 26895810). One study has reported loss of heterozygosity (LOH) on 9p21, which includes the region that encodes CDKN2A and CDKN2B, in 25% of papillary renal cell carcinoma tumors (Maestro et al., 2000; 11037653). Loss due to deletion or hypermethylation of chromosome 9p, which includes the CDKN2A and CDKN2B loci, has been reported at frequencies ranging from 13% to 80% of renal cell carcinoma samples, including ccRCC and papillary subtypes, and has been associated with poor prognosis (Toma et al., 2008; 18592004, Klatte et al., 2009; 19124809, Gunawan et al., 2003; 14559804, Onay et al., 2009; 19641369, Sanz_Casla et al., 2003; 12883879). In addition, loss of chromosome 9p has been associated with advanced tumor grade, disease progression, and overall poor prognosis in both ccRCC and papillary renal cell carcinoma (Klatte et al., 2009; 19124809, Grady et al., 2001; 11490304, Gunawan et al., 2003; 14559804). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "MLL2", "Include": "true", "Alterations": {"Alteration": {"Name": "Q836fs*3, H3037fs*34", "AlterationProperties": {"AlterationProperty": [{"dnaFraction": "17.92", "isEquivocal": "false", "name": "Q836fs*3"}, {"dnaFraction": "27.55", "isEquivocal": "false", "name": "H3037fs*34"}]}, "Interpretation": "MLL2 encodes an H3K4_specific histone methyltransferase that is involved in the transcriptional response to progesterone signaling (Vicent et al., 2011; 21447625). Germline de novo mutations of MLL2 are responsible for the majority of cases of Kabuki syndrome, a complex and phenotypically distinctive developmental disorder (Hannibal et al., 2011; 21671394). A significant number of inactivating MLL2 alterations have been observed in multiple tumor types, suggesting a tumor suppressor role (Fagan et al.,2019; 31128216). MLL2 alterations are observed in a number of solid tumor contexts (cBio_Zehir et al., 2017; 28481359), and are especially prevalent in lung squamous cell carcinoma (SCC) (Cancer Genome Atlas Research Network et al., 2012; 22960745) and small cell lung carcinoma (SCLC) (Augert et al., 2017; 28007623). MLL2 mutation was found to be an independent prognostic factor of poor PFS and OS in non_small cell lung cancer, but not in SCLC (Ardeshir_Larijani et al., 2018; 29627316). One study reported that MLL2 truncating mutations were more common in recurrent ovary granulosa cell tumors (GCT) compared with primary GCTs (24% [10/42] vs. 3.0% [1/32])(Hillman et al., 2018; 29950560). In a study of esophageal SCC, high MLL2 expression positively correlated with tumor stage, differentiation, and size, and negatively correlated with OS (Abudureheman et al., 2018; 29532228). There are no targeted therapies available to address genomic alterations in MLL2. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MUTYH", "Include": "true", "Alterations": {"Alteration": {"Name": "W142*", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "47.51", "isEquivocal": "false", "name": "W142*"}}, "Interpretation": "MUTYH (also known as MYH) encodes an enzyme involved in DNA base excision repair, and loss of function mutations in MUTYH result in increased rates of mutagenesis and promotion of tumorigenesis (David et al., 2007; 17581577). The two most frequently reported MUTYH loss of function mutations are G382D (also referred to as G396D) and Y165C (also referred to as Y179C) (Molatore et al., 2010; 19953527, Kundu et al., 2009; 19836313, D Agostino et al., 2010; 20418187, Hegde et al., 2014; 24310308, Aretz et al., 2013; 22872101). Numerous other MUTYH mutations have also been shown to result in loss of function (Molatore et al., 2010; 19953527, Kundu et al., 2009; 19836313, Ali et al., 2008; 18534194, D Agostino et al., 2010; 20418187). In general, somatic MUTYH mutations are infrequently reported across cancer types (COSMIC, 2023)(Tate et al., 2019; 30371878). Monoallelic MUTYH mutation occurs in 1_2% of the general population (Hegde et al., 2014; 24310308, Aretz et al., 2013; 22872101). There are conflicting data regarding the impact of monoallelic mutations on the risk of developing colorectal cancer (CRC) (Win et al., 2014; 24444654, Lubbe et al., 2009; 19620482, Jones et al., 2009; 19394335). Patients with MUTYH_mutated CRC were reported to have significantly improved OS compared with patients without MUTYH mutation (Nielsen et al., 2010; 21044966). There are no therapies or clinical trials available to address MUTYH alterations in cancer. One or more of the MUTYH variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with MUTYH_associated polyposis (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline biallelic MUTYH mutation causes MUTYH_associated polyposis (also known as MYH_associated polyposis or MAP), an autosomal recessive condition characterized by multiple colorectal adenomas and increased lifetime risk of colorectal cancer (CRC) (Hegde et al., 2014; 24310308, Sampson et al., 2003; 12853198, Sieber et al., 2003; 12606733, Al_Tassan et al., 2002; 11818965). MAP accounts for approximately 0.7% of all CRC cases and 2% of early_onset CRC cases (Hegde et al., 2014; 24310308). In contrast to CRC, the role of MUTYH mutation in the context of other cancer types is not well established (Rennert et al., 2012; 21952991, Zhang et al., 2006; 16492928, von der Th\u00fcsen et al., 2011; 21189386, Casper et al., 2014; 24420788, Smith et al., 2009; 20110747). Estimates for the prevalence of MAP in the general population range from 1:5,000_1:10,000 (Aretz et al., 2013; 22872101). Therefore, in the appropriate clinical context, germline testing of MUTYH is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high and MSI_low were each reported in 1% of cases in a study of 152 renal cell carcinomas (RCC) (Stoehr et al., 2012; 22378480). Another study reported that fewer than 1% of RCC cases had MSI_H status (Bratslavsky et al., 2021; 33775530). Published data investigating the prognostic implications of MSI in RCC are limited (PubMed, Jan 2023). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "NSD3 (WHSC1L1)", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "NSD3, also known as WHSC1L1, encodes an enzyme that mediates histone methylation (Kim et al., 2006; 16682010). NSD3 has been shown to be amplified in various cancers (Kang et al., 2013; 23011637, Chen et al., 2014; 24874471, Morishita et al., 2011; 21664949). In TCGA datasets, NSD3 amplification has been most frequently observed in lung squamous cell carcinoma (17%) (Cancer Genome Atlas Research Network., 2012; 22960745), breast invasive carcinoma (13%) (cBio_Ciriello et al., 2015; 26451490), bladder urothelial carcinoma (9%) (Cancer Genome Atlas Research Network., 2014; 24476821), and head and neck squamous cell carcinoma (9%) (HNSCC_Cancer Genome Atlas Network., 2015; 25631445) samples (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Amplification of at least 1 member of the NSD3_CHD8_BRD4 pathway has been associated with worse OS in ovarian high_grade serous carcinoma and endometrial cancer (Jones et al., 2017; 28781807). In endometrial cancers, amplification of this pathway was more frequent in endometrial serous and endometrioid serious_like carcinomas compared to low_grade endometrioid endometrial adenocarcinomas (Jones et al., 2017; 28781807). There are no targeted therapies available to address genomic alterations in NSD3.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R306*", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "31.53", "isEquivocal": "false", "name": "R306*"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 2.2_6.4% of clear cell renal cell carcinomas (RCCs) (cBio_Gerlinger et al., 2014; 24487277, Cancer Genome Atlas Research Network., 2013; 23792563, cBio_Guo et al., 2011; 22138691, cBio_Sato et al., 2013; 23797736), 2.5% of papillary RCCs (cBioPortal, Feb 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210), and 31% of chromophobe RCCs (cBio_Davis et al., 2014; 25155756). In the literature, TP53 mutations have been reported in 4_5% of clear cell RCCs and at a higher incidence of 11% in non_clear cell RCCs, with incidences of 11% and 24% in papillary and chromophobe RCCs, respectively (Szymanska et al., 2010; 20137853, Gad et al., 2007; 17133269). TP53 mutations have been reported as more common in ccRCC metastases compared to primary tumors (de Velasco et al., 2018; 29674707). Coexpression of p53, which has been found to mostly be wild_type, and MDM2 has been associated with poor prognosis in RCC, suggesting that targeting the p53_MDM2 pathway may be a potential therapeutic strategy for a subset of patients with RCC (Noon et al., 2012; 21756282). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "06", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "06"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Kidney carcinoma, including renal clear cell carcinoma, renal papillary carcinoma, and renal sarcomatoid carcinoma subtypes, harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 0_2% of cases have been reported to harbor high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421, Pal et al., 2018; 28592388). Renal cell carcinomas harbor an average TMB among solid tumors, with a median of approximately 1_2 non_synonymous somatic mutations per megabase in kidney clear_cell or papillary carcinoma (Lawrence et al., 2013; 23770567, Alexandrov et al., 2013; 23945592). For patients with ccRCC, increased TMB is associated with poor survival outcomes, higher tumor grade, and advanced pathological stage (Zhang et al., 2019; 31930049). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "ZNF703", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "ZNF703 encodes a transcriptional repressor that plays roles in stem cell proliferation, cell cycle progression, and other key cellular functions (Bazarov et al., 2011; 21635707, Sircoulomb et al., 2011; 21328542). Amplification of ZNF703 has been correlated with protein expression (Holland et al., 2011; 21337521, Sircoulomb et al., 2011; 21328542). ZNF703 was established as a breast cancer oncoprotein by studies showing that ZNF703 expression resulted in transformation and increased proliferation of cultured cells (Holland et al., 2011; 21337521, Slorach et al., 2011; 21317240, Sircoulomb et al., 2011; 21328542), as well as increased lung metastases in a breast cancer xenograft model (Slorach et al., 2011; 21317240). Amplification and high expression of ZNF703 has been observed in luminal B breast tumors, a subtype associated with aggressive disease progression and poor patient outcomes (Holland et al., 2011; 21337521, Sircoulomb et al., 2011; 21328542, Reynisdottir et al., 2013; 24156016). ZNF703 expression has also been linked with aggressive tumor characteristics in patients with gastric and colorectal cancers (Yang et al., 2014; 24481460, Ma et al., 2014; 25017610). Putative high_level amplification of ZNF703 has been reported with the highest frequency in breast carcinoma, bladder urothelial carcinoma, uterine carcinosarcoma, lung squamous cell carcinoma (SCC), esophageal carcinoma and head and neck SCC (5_13% of samples)(cBioPortal, 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). There are no available targeted therapies to directly address ZNF703 alterations in cancer. One preclinical study suggested that ZNF703 expression in breast cancer cell lines is associated with reduced sensitivity to tamoxifen through AKT_mTOR activation (Zhang et al., 2013; 23991038), although these findings have not been verified in the clinical setting.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "FGFR1", "Alteration": "amplification", "Title": "A Study of Pembrolizumab (MK_3475) in Combination With Belzutifan (MK_6482) and Lenvatinib (MK_7902), or Pembrolizumab/Quavonlimab (MK_1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK_6482_012)", "StudyPhase": "PHASE 3", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, CTLA_4, HIF2a, PD_1", "Locations": "Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Wenzhou (China), Xiamen (China), Ningbo (China), Hangzhou (China), Jiaxing (China)", "NCTID": "NCT04736706", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "amplification", "Title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PD_L1, FGFRs, RET, PDGFRA, VEGFRs, KIT, FLT3, CSF1R", "Locations": "Hangzhou (China), Shanghai (China), Dongguan (China), Guangzhou (China), Zhuhai (China), Benbu (China), Zhengzhou (China), Jinan (China), Dalian (China), Tianjin (China)", "NCTID": "NCT05024214", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "amplification", "Title": "To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors", "StudyPhase": "PHASE 2", "Target": "PD_1, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Hangzhou (China), Nanchang (China), Nanjing (China), Hefei (China), Changsha (China), Wuhan (China), Nanning (China), Chongqing (China), Beijing (China), Harbin (China)", "NCTID": "NCT05014828", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "amplification", "Title": "Study of Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "FGFR1, CSF1R, VEGFRs, PD_1", "Locations": "Shanghai (China), Beijing (China)", "NCTID": "NCT04169672", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "amplification", "Title": "Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors", "StudyPhase": "PHASE 2", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Shanghai (China)", "NCTID": "NCT05098847", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "amplification", "Title": "Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)", "StudyPhase": "PHASE 1", "Target": "ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Shanghai (China), Seoul (Korea, Republic of), Brisbane (Australia), Liverpool (Australia), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Haifa (Israel), Warszawa (Poland), Gdansk (Poland)", "NCTID": "NCT03564691", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "amplification", "Title": "A Study of MK_6482 in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK_6482_011)", "StudyPhase": "PHASE 3", "Target": "HIF2a, MET, ROS1, RET, VEGFRs, FGFRs, PDGFRA, KIT", "Locations": "Hwasun (Korea, Republic of), Fukuoka (Japan), Seoul (Korea, Republic of), Osakasayama (Japan), Suita (Japan), Kashihara (Japan), Toyoake (Japan), Hamamatsu (Japan), Yokohama (Japan), Tokyo (Japan)", "NCTID": "NCT04586231", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "amplification", "Title": "GI_101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1, CTLA_4", "Locations": "Daejeon (Korea, Republic of), Suwon_si (Korea, Republic of), Seoul (Korea, Republic of), North Carolina", "NCTID": "NCT04977453", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "amplification", "Title": "Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK_3475_03A)", "StudyPhase": "PHASE 1/2", "Target": "PD_1, HIF2a, LAG_3, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Songpagu (Korea, Republic of), Seoul (Korea, Republic of), Herston (Australia), Blacktown (Australia), Kogarah (Australia), Heidelberg (Australia), Haifa (Israel), Jerusalem (Israel), Petah Tiqwa (Israel), Ramat Gan (Israel)", "NCTID": "NCT04626479", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "amplification", "Title": "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK_3475_03B)", "StudyPhase": "PHASE 1/2", "Target": "HIF2a, CTLA_4, FGFRs, RET, PDGFRA, VEGFRs, KIT, ITL4, LAG_3, PD_1", "Locations": "Seoul (Korea, Republic of), Songpagu (Korea, Republic of), Herston (Australia), Blacktown (Australia), Kogarah (Australia), Melbourne (Australia), Jerusalem (Israel), Petah Tiqwa (Israel), Ramat Gan (Israel), Tel Aviv (Israel)", "NCTID": "NCT04626518", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss exons 2_8", "Title": "AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)_Null Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Tainan (Taiwan), Hong Kong (Hong Kong), Nagoya_shi (Japan), Chuo_ku (Japan), Kashiwa_shi (Japan), Camperdown (Australia), Halle (Saale) (Germany), Salzburg (Austria), Wuerzburg (Germany), Ulm (Germany)", "NCTID": "NCT05094336", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss exons 2_8", "Title": "Safety and Tolerability of TNG908 in Patients With MTAP_deleted Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Lyon (France), Villejuif (France), Missouri, Massachusetts, Tennessee, Texas, Virginia", "NCTID": "NCT05275478", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss exons 2_8", "Title": "Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Colorado, Massachusetts, New York, Tennessee, Texas", "NCTID": "NCT05245500", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "ERBB2, TROP2, PARP", "Locations": "Shanghai (China), Guangzhou (China), Seoul (Korea, Republic of), Chongqing (China), Chengdu (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Lublin (Poland), Warszawa (Poland)", "NCTID": "NCT04644068", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Darlinghurst (Australia), Adana (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel), Istanbul (Turkey), Antalya (Turkey), Brasov (Romania)", "NCTID": "NCT03742895", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Illinois, Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee", "NCTID": "NCT04497116", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "K91fs*13", "Title": "A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PARP, Pol theta", "Locations": "London (United Kingdom), Oklahoma, Connecticut, New York, Pennsylvania, Tennessee, Texas, Florida", "NCTID": "NCT04991480", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "27479139", "FullCitation": "Limm K, et al. PLoS ONE (2016) pmid: 27479139", "Include": "true"}, {"number": "1", "ReferenceId": "25387827", "FullCitation": "Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827", "Include": "true"}, {"number": "2", "ReferenceId": "21356366", "FullCitation": "Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366", "Include": "true"}, {"number": "3", "ReferenceId": "23265702", "FullCitation": "Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702", "Include": "true"}, {"number": "4", "ReferenceId": "19097084", "FullCitation": "Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084", "Include": "true"}, {"number": "5", "ReferenceId": "27068473", "FullCitation": "Marjon K, et al. Cell Rep (2016) pmid: 27068473", "Include": "true"}, {"number": "6", "ReferenceId": "26912361", "FullCitation": "Mavrakis KJ, et al. Science (2016) pmid: 26912361", "Include": "true"}, {"number": "7", "ReferenceId": "26912360", "FullCitation": "Kryukov GV, et al. Science (2016) pmid: 26912360", "Include": "true"}, {"number": "8", "ReferenceId": "25087184", "FullCitation": "Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184", "Include": "true"}, {"number": "9", "ReferenceId": "27929028", "FullCitation": "Wei R, et al. Sci Rep (2016) pmid: 27929028", "Include": "true"}, {"number": "10", "ReferenceId": "27556634", "FullCitation": "Zhao M, et al. BMC Genomics (2016) pmid: 27556634", "Include": "true"}, {"number": "11", "ReferenceId": "19887491", "FullCitation": "Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491", "Include": "true"}, {"number": "12", "ReferenceId": "16778103", "FullCitation": "Marc\u00e9 S, et al. Clin. Cancer Res. (2006) pmid: 16778103", "Include": "true"}, {"number": "13", "ReferenceId": "20500769", "FullCitation": "Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769", "Include": "true"}, {"number": "14", "ReferenceId": "16618867", "FullCitation": "Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867", "Include": "true"}, {"number": "15", "ReferenceId": "21412930", "FullCitation": "Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930", "Include": "true"}, {"number": "16", "ReferenceId": "25426549", "FullCitation": "Li CF, et al. Oncotarget (2014) pmid: 25426549", "Include": "true"}, {"number": "17", "ReferenceId": "26656376", "FullCitation": "He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376", "Include": "true"}, {"number": "18", "ReferenceId": "24969958", "FullCitation": "Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958", "Include": "true"}, {"number": "19", "ReferenceId": "16818274", "FullCitation": "Mirebeau D, et al. Haematologica (2006) pmid: 16818274", "Include": "true"}, {"number": "20", "ReferenceId": "26088413", "FullCitation": "Becker AP, et al. Pathobiology (2015) pmid: 26088413", "Include": "true"}, {"number": "21", "ReferenceId": "27433286", "FullCitation": "Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286", "Include": "true"}, {"number": "22", "ReferenceId": "26910893", "FullCitation": "Bistulfi G, et al. Oncotarget (2016) pmid: 26910893", "Include": "true"}, {"number": "23", "ReferenceId": "25407435", "FullCitation": "Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435", "Include": "true"}, {"number": "24", "ReferenceId": "23816148", "FullCitation": "Maccioni L, et al. BMC Cancer (2013) pmid: 23816148", "Include": "true"}, {"number": "25", "ReferenceId": "26635288", "FullCitation": "Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288", "Include": "true"}, {"number": "26", "ReferenceId": "27960044", "FullCitation": "Lin X, et al. Cancer Sci. (2017) pmid: 27960044", "Include": "true"}, {"number": "27", "ReferenceId": "27994653", "FullCitation": "Zhi L, et al. J Cancer (2016) pmid: 27994653", "Include": "true"}, {"number": "28", "ReferenceId": "23361049", "FullCitation": "Gu F, et al. Br. J. Cancer (2013) pmid: 23361049", "Include": "true"}, {"number": "29", "ReferenceId": "33450196", "FullCitation": "Kalev P, et al. Cancer Cell (2021) pmid: 33450196", "Include": "true"}, {"number": "30", "ReferenceId": "31350521", "FullCitation": "Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521", "Include": "true"}, {"number": "31", "ReferenceId": "31257072", "FullCitation": "Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072", "Include": "true"}, {"number": "32", "ReferenceId": "31287990", "FullCitation": "Srour N, et al. Cancer Cell (2019) pmid: 31287990", "Include": "true"}, {"number": "33", "ReferenceId": "30916320", "FullCitation": "Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320", "Include": "true"}, {"number": "34", "ReferenceId": "35041419", "FullCitation": "Smith CR, et al. J Med Chem (2022) pmid: 35041419", "Include": "true"}, {"number": "35", "ReferenceId": "31040154", "FullCitation": "Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154", "Include": "true"}, {"number": "36", "ReferenceId": "29844120", "FullCitation": "Tang B, et al. Cancer Res. (2018) pmid: 29844120", "Include": "true"}, {"number": "37", "ReferenceId": "24928612", "FullCitation": "Munshi PN, et al. Oncologist (2014) pmid: 24928612", "Include": "true"}, {"number": "38", "ReferenceId": "26751376", "FullCitation": "de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376", "Include": "true"}, {"number": "39", "ReferenceId": "19478948", "FullCitation": "Lubin M, et al. PLoS ONE (2009) pmid: 19478948", "Include": "true"}, {"number": "40", "ReferenceId": "22825330", "FullCitation": "Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330", "Include": "true"}, {"number": "41", "ReferenceId": "22252602", "FullCitation": "Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602", "Include": "true"}, {"number": "42", "ReferenceId": "21301207", "FullCitation": "Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207", "Include": "true"}, {"number": "43", "ReferenceId": "21282358", "FullCitation": "Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358", "Include": "true"}, {"number": "44", "ReferenceId": "17912432", "FullCitation": "Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432", "Include": "true"}, {"number": "45", "ReferenceId": "11987241", "FullCitation": "Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241", "Include": "true"}, {"number": "46", "ReferenceId": "18618081", "FullCitation": "Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081", "Include": "true"}, {"number": "47", "ReferenceId": "35379845", "FullCitation": "Alhalabi O, et al. Nat Commun (2022) pmid: 35379845", "Include": "true"}, {"number": "48", "ReferenceId": "20094046", "FullCitation": "Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046", "Include": "true"}, {"number": "49", "ReferenceId": "22648708", "FullCitation": "Kohler LH, et al. Virchows Arch. (2012) pmid: 22648708", "Include": "true"}, {"number": "50", "ReferenceId": "23182986", "FullCitation": "Kim HR, et al. J. Clin. Oncol. (2013) pmid: 23182986", "Include": "true"}, {"number": "51", "ReferenceId": "24508104", "FullCitation": "Andr\u00e9 F, et al. Lancet Oncol. (2014) pmid: 24508104", "Include": "true"}, {"number": "52", "ReferenceId": "24265351", "FullCitation": "Dienstmann R, et al. Ann. Oncol. (2014) pmid: 24265351", "Include": "true"}, {"number": "53", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "54", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "55", "ReferenceId": "25900027", "FullCitation": "Ho TH, et al. BMC Cancer (2015) pmid: 25900027", "Include": "true"}, {"number": "56", "ReferenceId": "31340094", "FullCitation": "Loriot Y, et al. N. Engl. J. Med. (2019) pmid: 31340094", "Include": "true"}, {"number": "57", "ReferenceId": "26324363", "FullCitation": "Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363", "Include": "true"}, {"number": "58", "ReferenceId": "28416604", "FullCitation": "Karkera JD, et al. Mol. Cancer Ther. (2017) pmid: 28416604", "Include": "true"}, {"number": "59", "ReferenceId": "35176457", "FullCitation": "Subbiah V, et al. Ann Oncol (2022) pmid: 35176457", "Include": "true"}, {"number": "60", "ReferenceId": "29848605", "FullCitation": "Pal SK, et al. Cancer Discov (2018) pmid: 29848605", "Include": "true"}, {"number": "61", "ReferenceId": "32208524", "FullCitation": "Pal SK, et al. Cancer (2020) pmid: 32208524", "Include": "true"}, {"number": "62", "ReferenceId": "32622884", "FullCitation": "Bahleda R, et al. Ann Oncol (2020) pmid: 32622884", "Include": "true"}, {"number": "63", "ReferenceId": "34551969", "FullCitation": "Meric_Bernstam F, et al. Cancer Discov (2022) pmid: 34551969", "Include": "true"}, {"number": "64", "ReferenceId": "32649766", "FullCitation": "Kasbekar M, et al. Blood Adv (2020) pmid: 32649766", "Include": "true"}, {"number": "65", "ReferenceId": "31405822", "FullCitation": "Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822", "Include": "true"}, {"number": "66", "ReferenceId": "34250399", "FullCitation": "Farouk Sait S, et al. JCO Precis Oncol (2021) pmid: 34250399", "Include": "true"}, {"number": "67", "ReferenceId": "30745300", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300", "Include": "true"}, {"number": "68", "ReferenceId": "28972963", "FullCitation": "Papadopoulos KP, et al. Br. J. Cancer (2017) pmid: 28972963", "Include": "true"}, {"number": "69", "ReferenceId": "29223982", "FullCitation": "Cheng FT, et al. J Natl Compr Canc Netw (2017) pmid: 29223982", "Include": "true"}, {"number": "70", "ReferenceId": "26055304", "FullCitation": "Khodadoust MS, et al. Leukemia (2016) pmid: 26055304", "Include": "true"}, {"number": "71", "ReferenceId": "31434701", "FullCitation": "Tanasi I, et al. Blood (2019) pmid: 31434701", "Include": "true"}, {"number": "72", "ReferenceId": "29119847", "FullCitation": "Strati P, et al. Leuk. Lymphoma (2018) pmid: 29119847", "Include": "true"}, {"number": "73", "ReferenceId": "27870574", "FullCitation": "Nogova L, et al. J. Clin. Oncol. (2017) pmid: 27870574", "Include": "true"}, {"number": "74", "ReferenceId": "31195180", "FullCitation": "Aggarwal C, et al. J Thorac Oncol (2019) pmid: 31195180", "Include": "true"}, {"number": "75", "ReferenceId": "15109494", "FullCitation": "Tarsounas M, et al. Cell (2004) pmid: 15109494", "Include": "true"}, {"number": "76", "ReferenceId": "21821141", "FullCitation": "Suwaki N, et al. Semin. Cell Dev. Biol. (2011) pmid: 21821141", "Include": "true"}, {"number": "77", "ReferenceId": "15162012", "FullCitation": "Sasaki MS, et al. Cytogenet. Genome Res. (2004) pmid: 15162012", "Include": "true"}, {"number": "78", "ReferenceId": "15781618", "FullCitation": "Smiraldo PG, et al. Cancer Res. (2005) pmid: 15781618", "Include": "true"}, {"number": "79", "ReferenceId": "27734215", "FullCitation": "Graffeo R, et al. Breast Cancer Res. Treat. (2016) pmid: 27734215", "Include": "true"}, {"number": "80", "ReferenceId": "22415235", "FullCitation": "Osher DJ, et al. Br. J. Cancer (2012) pmid: 22415235", "Include": "true"}, {"number": "81", "ReferenceId": "22652533", "FullCitation": "Pelttari LM, et al. J. Med. Genet. (2012) pmid: 22652533", "Include": "true"}, {"number": "82", "ReferenceId": "24130102", "FullCitation": "Guti\u00e9rrez_Enr\u00edquez S, et al. Int. J. Cancer (2014) pmid: 24130102", "Include": "true"}, {"number": "83", "ReferenceId": "21822267", "FullCitation": "Loveday C, et al. Nat. Genet. (2011) pmid: 21822267", "Include": "true"}, {"number": "84", "ReferenceId": "26261251", "FullCitation": "Song H, et al. J. Clin. Oncol. (2015) pmid: 26261251", "Include": "true"}, {"number": "85", "ReferenceId": "28646019", "FullCitation": "Rivera B, et al. Cancer Res. (2017) pmid: 28646019", "Include": "true"}, {"number": "86", "ReferenceId": "14704354", "FullCitation": "Miller KA, et al. Nucleic Acids Res. (2004) pmid: 14704354", "Include": "true"}, {"number": "87", "ReferenceId": "16236763", "FullCitation": "Gruver AM, et al. Mutagenesis (2005) pmid: 16236763", "Include": "true"}, {"number": "88", "ReferenceId": "16522646", "FullCitation": "Hinz JM, et al. Nucleic Acids Res. (2006) pmid: 16522646", "Include": "true"}, {"number": "89", "ReferenceId": "16717288", "FullCitation": "Wiese C, et al. Nucleic Acids Res. (2006) pmid: 16717288", "Include": "true"}, {"number": "90", "ReferenceId": "19327148", "FullCitation": "Gruver AM, et al. BMC Mol. Biol. (2009) pmid: 19327148", "Include": "true"}, {"number": "91", "ReferenceId": "30765603", "FullCitation": "Fernandes VC, et al. J Biol Chem (2019) pmid: 30765603", "Include": "true"}, {"number": "92", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "93", "ReferenceId": "27908594", "FullCitation": "Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594", "Include": "true"}, {"number": "94", "ReferenceId": "28588062", "FullCitation": "Kondrashova O, et al. Cancer Discov (2017) pmid: 28588062", "Include": "true"}, {"number": "95", "ReferenceId": "22986143", "FullCitation": "Wickramanayake A, et al. Gynecol. Oncol. (2012) pmid: 22986143", "Include": "true"}, {"number": "96", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "97", "ReferenceId": "26057125", "FullCitation": "Janatova M, et al. PLoS ONE (2015) pmid: 26057125", "Include": "true"}, {"number": "98", "ReferenceId": "28591191", "FullCitation": "Stafford JL, et al. PLoS ONE (2017) pmid: 28591191", "Include": "true"}, {"number": "99", "ReferenceId": "30111881", "FullCitation": "Konstanta I, et al. J. Hum. Genet. (2018) pmid: 30111881", "Include": "true"}, {"number": "100", "ReferenceId": "30165555", "FullCitation": "Chen X, et al. Ann. Oncol. (2018) pmid: 30165555", "Include": "true"}, {"number": "101", "ReferenceId": "21635707", "FullCitation": "Bazarov AV, et al. Breast Cancer Res. (2011) pmid: 21635707", "Include": "true"}, {"number": "102", "ReferenceId": "21328542", "FullCitation": "Sircoulomb F, et al. EMBO Mol Med (2011) pmid: 21328542", "Include": "true"}, {"number": "103", "ReferenceId": "21337521", "FullCitation": "Holland DG, et al. EMBO Mol Med (2011) pmid: 21337521", "Include": "true"}, {"number": "104", "ReferenceId": "21317240", "FullCitation": "Slorach EM, et al. Genes Dev. (2011) pmid: 21317240", "Include": "true"}, {"number": "105", "ReferenceId": "24156016", "FullCitation": "Reynisdottir I, et al. Cancer Med (2013) pmid: 24156016", "Include": "true"}, {"number": "106", "ReferenceId": "24481460", "FullCitation": "Yang G, et al. Oncol. Rep. (2014) pmid: 24481460", "Include": "true"}, {"number": "107", "ReferenceId": "25017610", "FullCitation": "Ma F, et al. Oncol. Rep. (2014) pmid: 25017610", "Include": "true"}, {"number": "108", "ReferenceId": "23991038", "FullCitation": "Zhang X, et al. PLoS ONE (2013) pmid: 23991038", "Include": "true"}, {"number": "109", "ReferenceId": "21447625", "FullCitation": "Vicent GP, et al. Genes Dev. (2011) pmid: 21447625", "Include": "true"}, {"number": "110", "ReferenceId": "21671394", "FullCitation": "Hannibal MC, et al. Am. J. Med. Genet. A (2011) pmid: 21671394", "Include": "true"}, {"number": "111", "ReferenceId": "31128216", "FullCitation": "Fagan RJ, et al. Cancer Lett. (2019) pmid: 31128216", "Include": "true"}, {"number": "112", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "113", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "114", "ReferenceId": "28007623", "FullCitation": "Augert A, et al. J Thorac Oncol (2017) pmid: 28007623", "Include": "true"}, {"number": "115", "ReferenceId": "29627316", "FullCitation": "Ardeshir_Larijani F, et al. Clin Lung Cancer (2018) pmid: 29627316", "Include": "true"}, {"number": "116", "ReferenceId": "29950560", "FullCitation": "Hillman RT, et al. Nat Commun (2018) pmid: 29950560", "Include": "true"}, {"number": "117", "ReferenceId": "29532228", "FullCitation": "Abudureheman A, et al. J. Cancer Res. Clin. Oncol. (2018) pmid: 29532228", "Include": "true"}, {"number": "118", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "119", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "120", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "121", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "122", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "123", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "124", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "125", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "126", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "127", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "128", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "129", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "130", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "131", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "132", "ReferenceId": "24487277", "FullCitation": "Gerlinger M, et al. Nat. Genet. (2014) pmid: 24487277", "Include": "true"}, {"number": "133", "ReferenceId": "23792563", "FullCitation": "Nature (2013) pmid: 23792563", "Include": "true"}, {"number": "134", "ReferenceId": "22138691", "FullCitation": "Guo G, et al. Nat. Genet. (2011) pmid: 22138691", "Include": "true"}, {"number": "135", "ReferenceId": "23797736", "FullCitation": "Sato Y, et al. Nat. Genet. (2013) pmid: 23797736", "Include": "true"}, {"number": "136", "ReferenceId": "25155756", "FullCitation": "Davis CF, et al. Cancer Cell (2014) pmid: 25155756", "Include": "true"}, {"number": "137", "ReferenceId": "20137853", "FullCitation": "Szyma\u0144ska K, et al. Cancer Lett. (2010) pmid: 20137853", "Include": "true"}, {"number": "138", "ReferenceId": "17133269", "FullCitation": "Gad S, et al. Br. J. Cancer (2007) pmid: 17133269", "Include": "true"}, {"number": "139", "ReferenceId": "29674707", "FullCitation": "de Velasco G, et al. Br. J. Cancer (2018) pmid: 29674707", "Include": "true"}, {"number": "140", "ReferenceId": "21756282", "FullCitation": "Noon AP, et al. BJU Int. (2012) pmid: 21756282", "Include": "true"}, {"number": "141", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "142", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "143", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "144", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "145", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "146", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "147", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "148", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "149", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "150", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "151", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "152", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "153", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "154", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "155", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "156", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "157", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "158", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "159", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "160", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "161", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "162", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "163", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "164", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "165", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "166", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "167", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "168", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "169", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "170", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "171", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "172", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "173", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "174", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "175", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "176", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "177", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "178", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "179", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "180", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "181", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "182", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "183", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "184", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "185", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "186", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "187", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "188", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "189", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "190", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "191", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "192", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "193", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "194", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "195", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "196", "ReferenceId": "22926558", "FullCitation": "Girgis AH, et al. Cancer Res. (2012) pmid: 22926558", "Include": "true"}, {"number": "197", "ReferenceId": "26895810", "FullCitation": "Malouf GG, et al. Eur. Urol. (2016) pmid: 26895810", "Include": "true"}, {"number": "198", "ReferenceId": "11037653", "FullCitation": "Maestro de las Casas ML, et al. Arch. Esp. Urol. (2000) pmid: 11037653", "Include": "true"}, {"number": "199", "ReferenceId": "18592004", "FullCitation": "Toma MI, et al. Neoplasia (2008) pmid: 18592004", "Include": "true"}, {"number": "200", "ReferenceId": "19124809", "FullCitation": "Klatte T, et al. J. Clin. Oncol. (2009) pmid: 19124809", "Include": "true"}, {"number": "201", "ReferenceId": "14559804", "FullCitation": "Gunawan B, et al. Cancer Res. (2003) pmid: 14559804", "Include": "true"}, {"number": "202", "ReferenceId": "19641369", "FullCitation": "Onay H, et al. Urol. Int. (2009) pmid: 19641369", "Include": "true"}, {"number": "203", "ReferenceId": "12883879", "FullCitation": "Sanz_Casla MT, et al. Urol. Res. (2003) pmid: 12883879", "Include": "true"}, {"number": "204", "ReferenceId": "11490304", "FullCitation": "Grady B, et al. J. Urol. (2001) pmid: 11490304", "Include": "true"}, {"number": "205", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "206", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "207", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "208", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "209", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "210", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "211", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "212", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "213", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "214", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "215", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "216", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "217", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "218", "ReferenceId": "31700061", "FullCitation": "Su D, et al. Nat Commun (2019) pmid: 31700061", "Include": "true"}, {"number": "219", "ReferenceId": "32923894", "FullCitation": "Tramontana TF, et al. JCO Precis Oncol (2020) pmid: 32923894", "Include": "true"}, {"number": "220", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "221", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "222", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "223", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "224", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "225", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "226", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "227", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "228", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "229", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "230", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "231", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "232", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "233", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "234", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "235", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "236", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "237", "ReferenceId": "22378480", "FullCitation": "Stoehr C, et al. Pathobiology (2012) pmid: 22378480", "Include": "true"}, {"number": "238", "ReferenceId": "33775530", "FullCitation": "Bratslavsky G, et al. Urol Oncol (2021) pmid: 33775530", "Include": "true"}, {"number": "239", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "240", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "241", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "242", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "243", "ReferenceId": "16682010", "FullCitation": "Kim SM, et al. Biochem. Biophys. Res. Commun. (2006) pmid: 16682010", "Include": "true"}, {"number": "244", "ReferenceId": "23011637", "FullCitation": "Kang D, et al. Genes Chromosomes Cancer (2013) pmid: 23011637", "Include": "true"}, {"number": "245", "ReferenceId": "24874471", "FullCitation": "Chen Y, et al. PLoS ONE (2014) pmid: 24874471", "Include": "true"}, {"number": "246", "ReferenceId": "21664949", "FullCitation": "Morishita M, et al. Biochim. Biophys. Acta (2011) pmid: 21664949", "Include": "true"}, {"number": "247", "ReferenceId": "26451490", "FullCitation": "Ciriello G, et al. Cell (2015) pmid: 26451490", "Include": "true"}, {"number": "248", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "249", "ReferenceId": "25631445", "FullCitation": "Nature (2015) pmid: 25631445", "Include": "true"}, {"number": "250", "ReferenceId": "28781807", "FullCitation": "Jones DH, et al. Mol Clin Oncol (2017) pmid: 28781807", "Include": "true"}, {"number": "251", "ReferenceId": "17581577", "FullCitation": "David SS, et al. Nature (2007) pmid: 17581577", "Include": "true"}, {"number": "252", "ReferenceId": "19953527", "FullCitation": "Molatore S, et al. Hum. Mutat. (2010) pmid: 19953527", "Include": "true"}, {"number": "253", "ReferenceId": "19836313", "FullCitation": "Kundu S, et al. DNA Repair (Amst.) (2009) pmid: 19836313", "Include": "true"}, {"number": "254", "ReferenceId": "20418187", "FullCitation": "D Agostino VG, et al. DNA Repair (Amst.) (2010) pmid: 20418187", "Include": "true"}, {"number": "255", "ReferenceId": "24310308", "FullCitation": "Hegde M, et al. Genet. Med. (2014) pmid: 24310308", "Include": "true"}, {"number": "256", "ReferenceId": "22872101", "FullCitation": "Aretz S, et al. Eur. J. Hum. Genet. (2013) pmid: 22872101", "Include": "true"}, {"number": "257", "ReferenceId": "18534194", "FullCitation": "Ali M, et al. Gastroenterology (2008) pmid: 18534194", "Include": "true"}, {"number": "258", "ReferenceId": "24444654", "FullCitation": "Win AK, et al. Gastroenterology (2014) pmid: 24444654", "Include": "true"}, {"number": "259", "ReferenceId": "19620482", "FullCitation": "Lubbe SJ, et al. J. Clin. Oncol. (2009) pmid: 19620482", "Include": "true"}, {"number": "260", "ReferenceId": "19394335", "FullCitation": "Jones N, et al. Gastroenterology (2009) pmid: 19394335", "Include": "true"}, {"number": "261", "ReferenceId": "21044966", "FullCitation": "Nielsen M, et al. J. Natl. Cancer Inst. (2010) pmid: 21044966", "Include": "true"}, {"number": "262", "ReferenceId": "12853198", "FullCitation": "Sampson JR, et al. Lancet (2003) pmid: 12853198", "Include": "true"}, {"number": "263", "ReferenceId": "12606733", "FullCitation": "Sieber OM, et al. N. Engl. J. Med. (2003) pmid: 12606733", "Include": "true"}, {"number": "264", "ReferenceId": "11818965", "FullCitation": "Al_Tassan N, et al. Nat. Genet. (2002) pmid: 11818965", "Include": "true"}, {"number": "265", "ReferenceId": "21952991", "FullCitation": "Rennert G, et al. Cancer (2012) pmid: 21952991", "Include": "true"}, {"number": "266", "ReferenceId": "16492928", "FullCitation": "Zhang Y, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16492928", "Include": "true"}, {"number": "267", "ReferenceId": "21189386", "FullCitation": "von der Th\u00fcsen JH, et al. J. Clin. Oncol. (2011) pmid: 21189386", "Include": "true"}, {"number": "268", "ReferenceId": "24420788", "FullCitation": "Casper M, et al. Fam. Cancer (2014) pmid: 24420788", "Include": "true"}, {"number": "269", "ReferenceId": "20110747", "FullCitation": "Smith LM, et al. Pancreatology (2009) pmid: 20110747", "Include": "true"}, {"number": "270", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "271", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "272", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "273", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "274", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "275", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "276", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "277", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "278", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "279", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "280", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "281", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "282", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "283", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "284", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "285", "ReferenceId": "28592388", "FullCitation": "Pal SK, et al. Eur. Urol. (2018) pmid: 28592388", "Include": "true"}, {"number": "286", "ReferenceId": "23770567", "FullCitation": "Lawrence MS, et al. Nature (2013) pmid: 23770567", "Include": "true"}, {"number": "287", "ReferenceId": "23945592", "FullCitation": "Alexandrov LB, et al. Nature (2013) pmid: 23945592", "Include": "true"}, {"number": "288", "ReferenceId": "31930049", "FullCitation": "Zhang C, et al. Ann Transl Med (2019) pmid: 31930049", "Include": "true"}, {"number": "289", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "290", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "291", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "292", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "293", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "294", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "295", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "296", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "297", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "298", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "299", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "300", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_02_15 20:16:18", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "831x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "6 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "KIDNEY", "disease_ontology": "Kidney carcinoma (NOS)", "flowcell_analysis": "2000027467", "gender": "female", "pathology_diagnosis": "mixed urothelial and neuroendocrine carcinoma", "percent_tumor_nuclei": "50", "pipeline_version": "v3.19.0", "purity_assessment": "37.5", "specimen": "ORD_1563049_01*US1493770.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1563049_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Kidney", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "836.39", "name": "SQ_US1493770.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4268", "cds_effect": "1568A>G", "depth": "813", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "42.68", "position": "chr13:32907183", "protein_effect": "H523R", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.083", "cds_effect": "49G>A", "depth": "892", "equivocal": "false", "functional_effect": "missense", "gene": "BCL6", "percent_reads": "8.3", "position": "chr3:187451433", "protein_effect": "D17N", "status": "unknown", "strand": "_", "transcript": "NM_001706", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.531", "cds_effect": "2425G>A", "depth": "855", "equivocal": "false", "functional_effect": "missense", "gene": "MSH2", "percent_reads": "53.1", "position": "chr2:47705625", "protein_effect": "E809K", "status": "unknown", "strand": "+", "transcript": "NM_000251", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.6641", "cds_effect": "1096G>T", "depth": "658", "equivocal": "false", "functional_effect": "missense", "gene": "MST1R", "percent_reads": "66.41", "position": "chr3:49939947", "protein_effect": "V366F", "status": "unknown", "strand": "_", "transcript": "NM_002447", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.2755", "cds_effect": "9109delC", "depth": "813", "equivocal": "false", "functional_effect": "frameshift", "gene": "MLL2", "percent_reads": "27.55", "position": "chr12:49432029", "protein_effect": "H3037fs*34", "status": "likely", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.1792", "cds_effect": "2506_2507insC", "depth": "636", "equivocal": "false", "functional_effect": "frameshift", "gene": "MLL2", "percent_reads": "17.92", "position": "chr12:49444959", "protein_effect": "Q836fs*3", "status": "likely", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.2548", "cds_effect": "1470delA", "depth": "730", "equivocal": "false", "functional_effect": "frameshift", "gene": "FLT3", "percent_reads": "25.48", "position": "chr13:28609758", "protein_effect": "V491fs*11", "status": "unknown", "strand": "_", "transcript": "NM_004119", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.4797", "cds_effect": "271_272insTA", "depth": "713", "equivocal": "false", "functional_effect": "frameshift", "gene": "RAD51D", "percent_reads": "47.97", "position": "chr17:33434458", "protein_effect": "K91fs*13", "status": "likely", "strand": "_", "transcript": "NM_002878", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.3622", "cds_effect": "2194G>A", "depth": "646", "equivocal": "false", "functional_effect": "missense", "gene": "KDR", "percent_reads": "36.22", "position": "chr4:55968136", "protein_effect": "E732K", "status": "unknown", "strand": "_", "transcript": "NM_002253", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.5169", "cds_effect": "5623C>T", "depth": "741", "equivocal": "false", "functional_effect": "missense", "gene": "EP300", "percent_reads": "51.69", "position": "chr22:41573338", "protein_effect": "P1875S", "status": "unknown", "strand": "+", "transcript": "NM_001429", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.3153", "cds_effect": "916C>T", "depth": "701", "equivocal": "false", "functional_effect": "nonsense", "gene": "TP53", "percent_reads": "31.53", "position": "chr17:7577022", "protein_effect": "R306*", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.4774", "cds_effect": "2935G>A", "depth": "685", "equivocal": "false", "functional_effect": "missense", "gene": "PARP1", "percent_reads": "47.74", "position": "chr1:226549698", "protein_effect": "V979M", "status": "unknown", "strand": "_", "transcript": "NM_001618", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.28", "cds_effect": "1817G>A", "depth": "700", "equivocal": "false", "functional_effect": "missense", "gene": "LTK", "percent_reads": "28.0", "position": "chr15:41797609", "protein_effect": "R606Q", "status": "unknown", "strand": "_", "transcript": "NM_002344", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.5378", "cds_effect": "2468T>G", "depth": "714", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH2", "percent_reads": "53.78", "position": "chr1:120493358", "protein_effect": "L823R", "status": "unknown", "strand": "_", "transcript": "NM_024408", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"allele_fraction": "0.4751", "cds_effect": "425G>A", "depth": "762", "equivocal": "false", "functional_effect": "nonsense", "gene": "MUTYH", "percent_reads": "47.51", "position": "chr1:45798627", "protein_effect": "W142*", "status": "likely", "strand": "_", "transcript": "NM_001048171", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "10", "equivocal": "false", "gene": "FGFR1", "number_of_exons": "18 of 18", "position": "chr8:38259351_38363070", "ratio": "2.03", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "MTAP", "number_of_exons": "7 of 8", "position": "chr9:21815410_21862058", "ratio": "0.6", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:21998748_22101832", "ratio": "0.59", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"copy_number": "12", "equivocal": "false", "gene": "WHSC1L1", "number_of_exons": "21 of 23", "position": "chr8:38135812_38205689", "ratio": "2.39", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "ZNF703", "number_of_exons": "2 of 2", "position": "chr8:37553497_37556192", "ratio": "1.74", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21853212_21998002", "ratio": "0.58", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1493770.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "6.03", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}